This page shows the latest Hodgkin lymphoma news and features for those working in and with pharma, biotech and healthcare.
It will also retain research and development responsibilities for bluebird’s oncology pipeline of cellular therapies, which are focused on non-Hodgkin’s lymphoma, acute myeloid leukaemia, next-generation multiple myeloma
ALCL is a rare form of non-Hodgkin lymphoma, and is characterised either as ALK-positive or ALK-negative disease. ... ALK-positive ALCL is the most common type and is a fast-growing lymphoma that causes T-cell mutations.
Since then, the immunotherapy has added an array of indications to its arsenal, including approvals for the treatment of head and neck squamous cell carcinoma, classical Hodgkin lymphoma (cHL), cervical cancer,
Tyvyt has also been approved in China for the treatment of relapsed or refractory classical Hodgkin’s lymphoma (cHL).
The disorder is just as serious and life-threatening as many rare blood cancers, including progressive non-Hodgkin’s lymphoma.
Interim analysis demonstrates improvement in progression-free survival. Merck &Co/MSD’s Keytruda has hit the primary endpoint in a confirmatory phase 3 trial in classical Hodgkin lymphoma (cHL), three years ... Patients with classical Hodgkin lymphoma
More from news
Approximately 6 fully matching, plus 207 partially matching documents found.
The fatality rate was higher for patients with lung cancer and non-Hodgkin Lymphoma, at 15.7% and 9.4%, respectively. ... It also builds on previous studies demonstrating the cost-effectiveness of Zarxio as primary prophylaxis within patients with lung
CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which
relapsed or refractory aggressive CD19+ Non-Hodgkin Lymphoma.
on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells).
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment of non-Hodgkin's lymphoma.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Naming diseases after people, places and animals has been common practice throughout the world for centuries, from the more current examples of Swine flu and Lyme disease to 19th century ... s Lymphoma and Parkinsons.
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’s B-cell lymphoma, on the basis of a trial
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...